Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis
- Authors
- Yoon, S.E.[Yoon, S.E.]; Jo, H.[Jo, H.]; Kang, E.-S.[Kang, E.-S.]; Cho, D.[Cho, D.]; Cho, J.[Cho, J.]; Kim, W.S.[Kim, W.S.]; Kim, S.J.[Kim, S.J.]
- Issue Date
- Apr-2022
- Publisher
- Springer Nature
- Citation
- Bone Marrow Transplantation, v.57, no.4, pp.641 - 648
- Indexed
- SCIE
SCOPUS
- Journal Title
- Bone Marrow Transplantation
- Volume
- 57
- Number
- 4
- Start Page
- 641
- End Page
- 648
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/96587
- DOI
- 10.1038/s41409-022-01605-w
- ISSN
- 0268-3369
- Abstract
- The role of upfront autologous stem cell transplantation (ASCT) remains unclear in patients with primary central nervous system lymphoma (PCNSL) receiving rituximab and high-dose methotrexate (MTX)-based chemotherapy. We analyzed the outcomes of upfront ASCT in 106 patients with PCNSL (median age, 64 years; range, 34–86) who received rituximab, MTX, vincristine, and prednisolone (R-MVP). The objective response rate was 88.7% (94/106) and included 46 complete responses (43.4%). Upfront ASCT was performed in 38 responders (median age, 51 years; range, 34–69), including 13 patients aged >60 years, after conditioning with busulfan (3.2 mg/kg, days 8 to 5) and thiotepa (5 mg/kg, days 4–3). For 56 responders ineligible for ASCT because of age >70 years, poor performance status, or refusal to undergo upfront ASCT, other consolidation treatments (n = 32) or observation (n = 24) were performed. With a median follow-up of 24.4 months (95% confidence interval, 20.7–28.0 months), no transplantation-related deaths occurred and seven patients relapsed after upfront ASCT. By contrast, 24 relapses occurred in patients who did not receive upfront ASCT. The progression-free and overall survival were significantly better in patients undergoing upfront ASCT (P = 0.001). Our real-world data suggest the benefit from upfront ASCT. © 2022, The Author(s), under exclusive licence to Springer Nature Limited.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.